• Preface.- The Genetic Basis of Kidney Cancer and Implications for Targeted Therapies.- Molecular Biology of Clear Cell Renal Carcinoma.- HIF Biology in RCC:  Implications for Signaling, Disease Progression, and Treatment.- Tissue Biomarkers in Renal Cell Carcinoma: Intermediate Endpoints in the Selection of Targeted Agents for RCC.- Molecular Characterization of Renal Cell Carcinoma.- Targeting The Vegf Pathway In Renal Cell Carcinoma.- Angiopoetins and Other Non-VEGF Antiangiogenic Targets In Advanced Renal Cell Carcinoma.- Towards Personalized Cancer Medicine.- Epigenetic Targeting and Histone Deacetylase Inhibition in RCC.- C-MET as a Novel Target for the Treatment of Renal Cell Carcinoma.- Characterizing and Modulating the Tumor Micro-Environment in Renal Cell Carcinoma: Potential Therapeutic Strategies.- Carbonic Anhydrase IX:  Its role as a biomarker, diagnostic, and therapeutic target in Renal Cell Carcinoma.- Presurgical Therapy for Renal Cell Carcinoma and Implications for Window of Opportunity Trials.- Mechanisms of Resistance to VEGF Directed Therapy and Implications for Future Trial Design.- Vaccine Based Immunotherapy and Targeting the Tumor Microenvironment in Renal Cell Carcinoma.- Index.

From the reviews: "The book Renal Cell Carcinoma: Translational Biology, Personalized Medicine, and Novel Therapeutic Agents comes in a timely fashion, as we are experiencing major advancements in our understanding of the basic biology of renal cell carcinoma (RCC) and their applications in clinical practice. ... certainly appeal to a wide range of readers interested in the research aspect of RCC, such as graduate and medical students, postdoctoral fellows, as well as basic scientists and clinicians interested in the basic and translational research in RCC." (Jose A. Karam and Christopher G. Wood, Urology, Vol. 81 (1), January, 2013) "Editors Figlin, Rathmell and Rini, with the help of 20 contributors compiled recent advances in biology and related therapeutic aspects. ... We recommend this excellent textbook to practitioners and researchers involved in kidney cancer. The high quality level of the text and the outstanding illustrations makes this book an essential purchase." (European Urology Today, June-July, 2012) "This book by Figlin et al. is ... timely, and serves to bring the reader up-todate with what has been a tremendously exciting time in the field. ... We found it comprehensive, well written and well illustrated. ... Overall, we found this to be an excellent book that we highly recommend. ... It would be equally well placed on the shelf of physicians and researchers ... and those with an interest in the field would do well to have read it." (Naveen S. Vasudev and James M. G. Larkin, British Journal of Clinical Pharmacology, Summer, 2012)

• Preface.- The Genetic Basis of Kidney Cancer and Implications for Targeted Therapies.- Molecular Biology of Clear Cell Renal Carcinoma.- HIF Biology in RCC:  Implications for Signaling, Disease Progression, and Treatment.- Tissue Biomarkers in Renal Cell Carcinoma: Intermediate Endpoints in the Selection of Targeted Agents for RCC.- Molecular Characterization of Renal Cell Carcinoma.- Targeting The Vegf Pathway In Renal Cell Carcinoma.- Angiopoetins and Other Non-VEGF Antiangiogenic Targets In Advanced Renal Cell Carcinoma.- Towards Personalized Cancer Medicine.- Epigenetic Targeting and Histone Deacetylase Inhibition in RCC.- C-MET as a Novel Target for the Treatment of Renal Cell Carcinoma.- Characterizing and Modulating the Tumor Micro-Environment in Renal Cell Carcinoma: Potential Therapeutic Strategies.- Carbonic Anhydrase IX:  Its role as a biomarker, diagnostic, and therapeutic target in Renal Cell Carcinoma.- Presurgical Therapy for Renal Cell Carcinoma and Implications for Window of Opportunity Trials.- Mechanisms of Resistance to VEGF Directed Therapy and Implications for Future Trial Design.- Vaccine Based Immunotherapy and Targeting the Tumor Microenvironment in Renal Cell Carcinoma.- Index.

From the reviews: "The book Renal Cell Carcinoma: Translational Biology, Personalized Medicine, and Novel Therapeutic Agents comes in a timely fashion, as we are experiencing major advancements in our understanding of the basic biology of renal cell carcinoma (RCC) and their applications in clinical practice. ... certainly appeal to a wide range of readers interested in the research aspect of RCC, such as graduate and medical students, postdoctoral fellows, as well as basic scientists and clinicians interested in the basic and translational research in RCC." (Jose A. Karam and Christopher G. Wood, Urology, Vol. 81 (1), January, 2013) "Editors Figlin, Rathmell and Rini, with the help of 20 contributors compiled recent advances in biology and related therapeutic aspects. ... We recommend this excellent textbook to practitioners and researchers involved in kidney cancer. The high quality level of the text and the outstanding illustrations makes this book an essential purchase." (European Urology Today, June-July, 2012) "This book by Figlin et al. is ... timely, and serves to bring the reader up-todate with what has been a tremendously exciting time in the field. ... We found it comprehensive, well written and well illustrated. ... Overall, we found this to be an excellent book that we highly recommend. ... It would be equally well placed on the shelf of physicians and researchers ... and those with an interest in the field would do well to have read it." (Naveen S. Vasudev and James M. G. Larkin, British Journal of Clinical Pharmacology, Summer, 2012)

• Preface.- The Genetic Basis of Kidney Cancer and Implications for Targeted Therapies.- Molecular Biology of Clear Cell Renal Carcinoma.- HIF Biology in RCC:  Implications for Signaling, Disease Progression, and Treatment.- Tissue Biomarkers in Renal Cell Carcinoma: Intermediate Endpoints in the Selection of Targeted Agents for RCC.- Molecular Characterization of Renal Cell Carcinoma.- Targeting The Vegf Pathway In Renal Cell Carcinoma.- Angiopoetins and Other Non-VEGF Antiangiogenic Targets In Advanced Renal Cell Carcinoma.- Towards Personalized Cancer Medicine.- Epigenetic Targeting and Histone Deacetylase Inhibition in RCC.- C-MET as a Novel Target for the Treatment of Renal Cell Carcinoma.- Characterizing and Modulating the Tumor Micro-Environment in Renal Cell Carcinoma: Potential Therapeutic Strategies.- Carbonic Anhydrase IX:  Its role as a biomarker, diagnostic, and therapeutic target in Renal Cell Carcinoma.- Presurgical Therapy for Renal Cell Carcinoma and Implications for Window of Opportunity Trials.- Mechanisms of Resistance to VEGF Directed Therapy and Implications for Future Trial Design.- Vaccine Based Immunotherapy and Targeting the Tumor Microenvironment in Renal Cell Carcinoma.- Index.

From the reviews: "The book Renal Cell Carcinoma: Translational Biology, Personalized Medicine, and Novel Therapeutic Agents comes in a timely fashion, as we are experiencing major advancements in our understanding of the basic biology of renal cell carcinoma (RCC) and their applications in clinical practice. ... certainly appeal to a wide range of readers interested in the research aspect of RCC, such as graduate and medical students, postdoctoral fellows, as well as basic scientists and clinicians interested in the basic and translational research in RCC." (Jose A. Karam and Christopher G. Wood, Urology, Vol. 81 (1), January, 2013) "Editors Figlin, Rathmell and Rini, with the help of 20 contributors compiled recent advances in biology and related therapeutic aspects. ... We recommend this excellent textbook to practitioners and researchers involved in kidney cancer. The high quality level of the text and the outstanding illustrations makes this book an essential purchase." (European Urology Today, June-July, 2012) "This book by Figlin et al. is ... timely, and serves to bring the reader up-todate with what has been a tremendously exciting time in the field. ... We found it comprehensive, well written and well illustrated. ... Overall, we found this to be an excellent book that we highly recommend. ... It would be equally well placed on the shelf of physicians and researchers ... and those with an interest in the field would do well to have read it." (Naveen S. Vasudev and James M. G. Larkin, British Journal of Clinical Pharmacology, Summer, 2012)